Brief: Pixium Vision Announces Positive Long-Term Follow-Up Data For The Prima Implant

Pixium Vision SA

13/10/2021 06:13

Oct 13 (Reuters) - Pixium Vision SA  ALPIX.PA :
    * ANNOUNCES POSITIVE LONG-TERM FOLLOW-UP DATA FOR THE PRIMA
IMPLANT FROM THE FRENCH FEASIBILITY STUDY OF THE PRIMA SYSTEM
    * PRIMA IMPLANT IS WELL TOLERATED AND SAFE FOR PATIENTS 36
MONTHS
AFTER IMPLANTATION
    * IMPLANT IS VERY STABLE; NO DETERIORATION OBSERVED DURING
ITS
LIFETIME
    * PRIMA ALLOWS A SIGNIFICANT POTENTIAL IMPROVEMENT IN VISUAL
ACUITY
    * FOLLOWING THE POSITIVE RESULTS OF THE FRENCH FEASIBILITY
STUDY,
THE EUROPEAN PIVOTAL PRIMAVERA STUDY HAS STARTED FOR PRIMA
IMPLANTS AND THE PRIMA SYSTEM
    * THE STUDY WILL INCLUDE THREE YEARS OF FOLLOW-UP, WITH
ASSESSMENT
OF THE MAIN EVALUATION CRITERIA 12 MONTHS AFTER IMPLANTATION

Source text for Eikon:  ID:nGNEb1vgRk 
Further company coverage:  ALPIX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))